Redefining Autoimmune Interstitial Lung Disease Journey: From Early Risk Recognition to Long-term Care
Objectives:
Autoimmune diseases are a major cause of interstitial lung disease (ILD), with pulmonary fibrosis driving morbidity and mortality. This session will examine risk identification, key clinical and radiological signals of progression, and translation of guidelines into personalised care, concluding with emerging concepts and innovations shaping the future management of autoimmune ILD.
| Agenda - Saturday 31 October | |
|---|---|
|
|
Chairperson: Prof Shin-Seok Lee, Republic of Korea
|
|
1250-1255
|
Opening and welcome remarks Prof Shin-Seok Lee, Republic of Korea |
|
1255-1310
|
What We Don’t See: The Hidden Burden of Autoimmune-ILD Prof Andrea Low, Singapore |
|
1310-1325
|
Guidelines Today: Recommendation and Remaining Gaps Prof Anna Hoffman-Vold, Norway |
|
1325-1340
|
The Mechanism of PDE4B Inhibition Dr Matthew Parker, Australia |
|
1340-1400
|
Evolving Treatment Landscape in Autoimmune-ILD Prof Mandana Nikpour, Australia |
|
1400-1410
|
Q&A Prof Shin-Seok Lee, Republic of Korea; Prof Andrea Low, Singapore; Prof Anna Hoffman-Vold, Norway; Prof Mandana Nikpour, Australia; Dr Matthew Parker, Australia |
|
1410-1415
|
Closing remarks Prof Shin-Seok Lee, Republic of Korea |
